Navigation Links
Gene found to play a suppressor role in skin cancer development
Date:2/6/2008

Researchers at the Burnham Institute for Medical Research (Burnham Institute) have provided genetic evidence that Activating Transcription Factor 2 (ATF2) plays a suppressor role in skin cancer development. ATF2 is a protein that regulates gene transcription, which is the first step in the translation of genetic code, in response to extracellular stresses such as ultraviolet light and ionizing radiation. This function of ATF2 in stress and DNA damage response suggests that it may also play a role in the formation of tumors.

Previous studies led by Zeev Ronai, Ph.D. have suggested an important role of ATF2 in melanoma development and progression. In this new study, published in this weeks issue of Proceedings of the National Academy of Sciences of the United States of America, the Ronai laboratory, in collaboration with Nic Jones, Ph.D. from the University of Manchester UK, used a mouse model that expresses a transcriptionally inactive form of ATF2 in skin cells (keratinocytes). When the mice were subjected to chemically mediated skin carcinogenesis, tumors appeared faster and more frequently. These findings reveal that loss of ATF2 transcriptional activity in skin exposed to carcinogens enhances skin tumor formation, suggesting a tumor suppressor role for ATF2 in keratinocytes.

Important support for the finding comes from the analysis of tumor samples from human patients with non malignant skin cancer, states Dr. Ronai. Unlike the strong nuclear expression of ATF2 in normal skin, squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) samples exhibit a significantly reduced nuclear staining for ATF2.

The analysis of human skin cell carcinomas are also consistent with the reduced expression of ATF2 found in the papillomas that developed in the wild-type animals in this study, supporting the notion that ATF2 needs to be inactivated to support skin tumor development.

The group also identified ATF2 as an upstream regulator of genes including Presenilin1 (PS1), Notch1, and -catenin, all of which have previously been reported to be involved in skin tumor development; thus providing an example of a mechanism by which ATF2 functions as a tumor suppressor.


'/>"/>

Contact: Andrea Moser
communications@burnham.org
858-646-3146
Burnham Institute
Source:Eurekalert  

Related medicine news :

1. Very young found to process fear memories in unique way
2. Texas Senator Tommy Williams Honored as Champion for Children by the AMERIGROUP Foundation
3. Foundations to Strengthen State Health Care Reform Advocacy
4. Agatston Research Foundation Sponsors New Childhood Obesity Initiative
5. LOreal USA Announces Three-Year Support of Womens Dermatologic Society Foundation Community Outreach
6. Avon Foundation Brings Together Breast Cancer Experts in Houston to Report Significant New Data
7. 2 genes found to play crucial role in cell survival
8. Model found to determine cause, possible treatment of nerve tumors
9. R Baby Foundation Raises $2.5 Million in First Year
10. Simons Foundation grant boosts brain tumor research
11. The Chrysler Foundation and Kenosha Engine Plant Donate $100,000 to New YMCA Aquatics Center
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene found to play a suppressor role in skin cancer development
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
Breaking Medicine Technology: